Idorsia And J&J Hypertension Drug Edges Closer To An Uncertain Market
The partners released positive data from a Phase III study of their resistant hypertension drug candidate, aprocitentan, and have already started talks with regulators, but its commercial prospects remain uncertain.
You may also be interested in...
Idorsia, the Swiss company spun out of Actelion after the latter was bought by J&J, is to get another windfall from the US major which has triggered an option to co-develop the Phase III-ready drug aprocitentan.
Emerging Company Profile: The private German biotech Ariceum has just launched with a €25m financing to advance its lead radioligand candidate, satoreotide, into Phase I development and hopes its antagonist approach could give Novartis’s Lutathera a run for its money.
The US firm released promising interim data from a mid-stage Becker muscular dystrophy trial, claiming success here could translate to Duchenne as it unveiled plans for more studies across similar conditions.